The primary objective of this study was to compare the risk of major cardiovascular events (MACE) in a large observational cohort of rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritis (AxSpA) patients
Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory disease, leading to joint deformity, disability and an excess mortality, largely attributable to cardiovascular and cerebrovascular disease (1, 2) . This increased cardiovascular (CV) risk is not explained solely by an increase in traditional CV risk factors, thus suggesting that RA is an independent risk factor (3) (4) (5) . Similarly, psoriatic arthritis (PsA) and
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ankylosing spondylitis (AS), seem to confer also an increased risk of cardiovascular diseases (CVD) (6) (7) (8) . The increase in CV risk has been evaluated in a recent meta-analysis on PsA to be 43% for cardiovascular diseases and 22% for cerebrovascular diseases, independently from traditional cardiovascular risk factors (9) . In AS, the relative risk of acute coronary syndrome compared to the general population varies from 1.4 (95% IC 1.2-1.4) to 3.0 (95% IC 1.3-6.7), depending on the study (10) . Schier et al. estimated the relative risk of myocardial infarction in RA compared to the general population at 1.52 (95% IC 1.37-1.69) in their meta-analysis (11) .
Inflammation has been shown to play an important role in the pathogenesis of atherosclerosis, and systemic markers of inflammation predict cardiovascular disease in the general population (12) . RA and atherosclerosis share similar processes in their pathogenesis, with implication of immune cells, adhesion molecules, endothelin and pro-inflammatory cytokines, suggesting that the systemic inflammation present in RA accelerates atherogenesis (13, 14) . Disease modifying antirheumatic drugs (DMARDs) such as methotrexate (MTX) or tumor necrosis factor (TNF) inhibitors decrease the risk of CV morbidity and mortality in RA and psoriasis, supporting the role of systemic inflammation in atherogenesis (15) (16) (17) (18) .
It is not known if this increased CV risk is similar between various rheumatic diseases. In particular, the prevalence and incidence of major adverse cardiovascular events (MACE) between RA, PsA and axial spondyloarthritis (AxSpA) have not been directly compared in a large population cohort so far. The purpose of this study was to compare the prevalence and incidence of MACE between these inflammatory diseases after adjusting for traditional CV risk factors in a Swiss cohort of patients. The secondary objective was to find predictors of the incidence of MACE in the RA population, since this was the largest group of patients with available data.
Patients and Methods

Study design
We conducted a mixed retrospective and prospective cohort study using data from patients with RA, PsA and axSpA included in the Swiss Clinical Quality Management (SCQM) registry. The SCQM registry is a longitudinal cohort of patients, which has been described in detail elsewhere (19) . Ethical approval for the SCQM and related studies was obtained from the Swiss Academy of Medical Sciences review board, and all the patients have provided written consent prior to enrolment. At inclusion, demographic and disease characteristics, concomitant treatments, and co-morbidities are collected by the treating rheumatologists and patients fill-out self-administered questionnaires such as health assessment questionnaire disability index (HAQ-DI). Follow-up assessments are performed at regular intervals, approximately one to four times a year (disease activity, antirheumatic treatments, side effects, reasons of discontinuation, co-morbidities, etc.). The Swiss Society of Rheumatology recommends the inclusion of all the patients treated with biologic DMARDs (bDMARDs). Patients in SCQM come from diverse clinical settings, with more than 50% from private practice, 30 % from non-academic centres and 20 % from academic centres.
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For this study, we added a specific self-reported questionnaire asking the patients for CV events and associated risk factors, encompassing the period before the inclusion in the register, to the existing longitudinal data collection. When available we also included in the analysis the data regarding CV risks factors that were captured prospectively in the SCQM registry by the treating rheumatologists. For patients lost of follow-up (no follow-up visit ≥ 18 months) as well as in cases with incomplete or inconsistent responses, we asked the treating rheumatologists for further information or confirmation of patient-reported data. In patients lost of follow-up, we enquired if the patients had died and if so, whether the cause of death was related to a CV event. Because this procedure required de-anonymization of part of the data in order to contact the treating rheumatologist, we obtained a separate approval for this study by the Ethics Committee of the Geneva University Hospitals.
For the analysis of incidence rates, inclusion criteria were a diagnostic of RA, PsA, or axSpA established by the treating rheumatologist, age ≥ 18 years at disease onset, and at least at one visit after disease onset and between March 2012 (start of collection of patient cardiovascular risk questionnaire) and March 2015 (end of the study and locking of the database). Exclusion criteria were a history of non-lethal MACE at time of disease onset and the non-completion of the cardiovascular questionnaire.
For the analysis of prevalence, inclusion criteria were a diagnostic of RA, PsA, or axSpA established by the treating rheumatologist and age ≥ 18 years at disease onset and at least one answer to the questionnaire between March 2012 and March 2015.
For the secondary objective of analyzing factors associated with the incidence of cardiovascular diseases in RA, we restricted our analysis to the subgroup of RA patients who experienced a MACE after their inclusion in the SCQM registry and were free of MACE before inclusion in SCQM.
Outcome of interest
MACE was defined as myocardial infarction, transient or permanent cerebrovascular event, or CVassociated death. For the calculation of an incidence rate of MACE, we recorded the year of occurrence from time of disease onset until the last visit before the end of study. The exposure time was defined as the time in years between onset of the rheumatic disease until either the first MACE or the end of follow-up, whichever occurred first. For patients who died from a CV event, we recorded the year at the last visit. For the prevalence, we considered all visits in the study period with complete information regarding non-lethal myocardial infarction and non-lethal stroke, to derive presence of a history of non-lethal MACE.
Exposure of interest and covariates
Of primary interest was the type of inflammatory rheumatic disease: RA, PsA, or axSpA. In addition to the year of disease onset, sex and age at disease onset, and disease duration, we assessed the following other traditional CV risk factors: known family history of early MACE, as defined by a MACE occurring before the age of 50 in a first-degree relative, ever-hypertension, ever-diabetes, everhyperlipidemia (hypercholesterolemia was not specifically captured in the questionnaire), and eversmoking. All available information as provided by the patient until end of follow-up was considered and the value set to "yes" in case the patient indicated presence of such a condition at least once.
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Other variables of interest
For the RA patients, we assessed the medication history with respect to bDMARDs and use of MTX, glucocorticoids (GC), and nonsteroidal anti-inflammatory drugs (NSAIDs). We also assessed seropositivity for rheumatoid factor and/or anti-citrullinated protein antibodies, Health Assessment Questionnaire Disability Index (HAQ-DI) and Disease Activity Score (DAS)28-CRP at the time of inclusion in the SCQM registry.
Statistical analyses
We compared covariates between diseases using the Kruskal-Wallis test for continuous or discrete variables and the Fisher's exact test for categorical variables. To estimate and compare incidence rates of first MACE between diseases, and for the analysis of predictors of MACE in RA, we applied Poisson regression with offsets corresponding to the patients' time under observation for the first MACE. For the analysis of prevalence, we applied logistic regression to estimate and compare the odds for a history of non-lethal MACE between diseases. Due to the relatively small number of MACE, we restricted the number of variables to include in the multivariable models (20) . We included all cardiovascular risk factors and disease duration to ensure the best possible adjustment for confounding. However, other characteristics were only added to the multiple adjusted model if their p-values were <0.1 in the univariable model (21) . A significance level of 0.05 was used and no correction for multiple testing was applied, as all the analysis performed were pre-specified. For missing values of covariates, we performed a multiple imputation analysis using chained equations. All analyses were performed using R v.3.3.2 and the mice package.
Results
5,315 patients were eligible for the analysis of incidence (Figure 1 ) and contributed a total follow-up time of 37'495 patient years for RA, 19,837 for AxSpA, and 9,171 for PsA. Rheumatic diseases started between 1950 and 2014 and differed significantly with respect to assessed CV risk factors and disease duration (Table 1) . A total of 100 RA, 28 AxSpA, and 13 PsA patients experienced at least one incident MACE since disease onset. The unadjusted incidence rate of MACE per 1000 person-years was 2.67 for RA, 1.41 for AxSpA, and 1.42 for PsA (p = 0.005). Compared to RA patients, unadjusted incidence rate ratio (IRR) were 0.53 for AxSpA (p=0.003) and 0.53 for PsA (p=0.03). IRR adjusted for gender were 0.34 for AxSpA (p<0.001) and 0.37 for PsA (p=0.001), whereas IRR adjusted for age were 1.16 for AxSpA (p=0.52) and 0.75 for PsA (p=0.34). The age-adjusted IRR strongly swayed the IRR toward 1 (the null), suggesting that age is an important confounder when comparing incidence rates across rheumatic diseases.
When we further adjusted for traditional CV risk factors, age at disease onset, gender, and disease duration, the difference between RA and AxSpA was no longer statistically significant (adjusted IRR: 0.93, 95% confidence interval (CI): 0.51-1.69, p=0.80), nor between RA and PsA (adjusted IRR: 0.56, 95% CI: 0.27-1. 14, p=0.11) . Older age at disease onset, male gender, known familial history, everhypertension, ever-hyperlipidemia, and longer disease duration were significantly positively associated with the risk of incident MACE ( Table 2 ).
In the analysis of prevalent MACE, we included 3,164 RA, 1,487 AxSpA and 805 PsA. The unadjusted prevalence of non-lethal MACE was 4.84% for RA, 2.22% for AxSpA and 2.86% for PsA (p < 0.001). After adjusting for the traditional CV risk factors, age at disease onset, gender, and disease duration,
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the difference was no longer significant between RA and AxSpA (prevalence ratio (PR) 0.98, 95% CI 0.58-1.61) and between RA and PsA (PR 0.66, 95% CI 0.37-1.12). As for the incident MACE, the most important confounder was age, and adjusting only for this variable removed the statistical significant differences in prevalence of MACE between diseases (Table 3) .
For the predictors of the incidence of MACE in RA, 3019 patients were eligible for analysis with 49 events. In univariable analysis, age, male gender, ever-smoking, ever-hypertension, everhyperlipidemia and HAQ-DI were statistically significantly associated with the occurrence of MACE, whereas seropositivity and use of NSAIDs were negatively associated (Table 4 ). When adjusting for age and gender only, seropositivity and NSAIDs were no longer associated with the occurrence of MACE. In multivariable analysis, age, male gender, ever-smoking, ever-hyperlipidemia and disease duration were significantly associated with the occurrence of MACE. Ever-hypertension, everdiabetes, and HAQ-DI at inclusion were not associated with the occurrence of MACE.
Discussion
In this study, we did not find an independent association between the type of rheumatic disease and the incidence and prevalence of MACE. The apparent increase in MACE in RA as compared to PsA and AxSpA was largely attributable to difference in population characteristics, in particular owing to older age. In the RA population, age, gender, ever-smoking, ever-hyperlipidemia and disease duration were independent predictors of the incidence of MACE.
A study from Jamnitski et al. directly compared the incidence of MACE between RA and PsA patients. The study was limited to 489 PsA and 353 RA patients aged between 50 and 75 years, who answered a mailed questionnaire (22) . There was no difference in the odds of MACE between RA and PsA after stratification by age and sex. In a meta-regression with adjustment for age and sex only, there was also no difference between RA and PsA in the risk of myocardial infarction (11) . We only found one cross-sectional study reporting significantly lower odds of CVD in patients with PsA (n=1,147) compared to RA patients (n=2,152), after adjustments for demographic variables, traditional CV risk factors and educational level [OR 0.46 (0.23-0.92), p=0.028) (23) . In a recent study linking national and population-based registers, the age and sex-adjusted relative risks for acute coronary syndrome compared with the general population was 1.3 (95% CI 1.0 to 1.7) for AS and 1.7 (1.4 to 2.0) for RA. For stroke, the relative risks were 1.5 (1.1 to 2.0) in AS and 1.5 (1.2 to 1.8) in RA, compared with the general population. The important overlap between the relative risks suggests that the CV risk is comparable in RA and AS (24) . We found one study that directly compared AS and RA, with a lower hazard ratio for myocardial infarction of 0.8 (95% IC 0.7-0.9) in AS as compared to RA, but no significant difference in the hazard of stroke (10) .
Inflammation is likely to play an important role in the pathogenesis of atherosclerosis, which may explain a similar risk of MACE in RA, PsA and AxSpA. Endothelial activation, infiltration of inflammatory cells in the blood vessel walls, secretion of chemokines and cytokines and formation of a plaque by macrophages turned into foam cells are present in atherosclerosis (13, 25) . The pathogenesis of RA is very similar to that of atherosclerosis with endothelial cell activation, recruitment of inflammatory cells, and cytokines release (26) . In particular, TNF may accelerate atherosclerosis in RA (27) and TNF is also implicated in the pathogenesis of AxSpA and PsA (28) (29) (30) . In fact, myocardial dysfunction and early signs of atherosclerosis have been shown in patients with AxSpA and AS (31, 32) . In addition, the IL-17/IL23 axis that exerts an important role in the
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This article is protected by copyright. All rights reserved. pathogenesis of AxSpA and PsA (33, 34) , has also been shown to contribute to endothelial dysfunction and arterial hypertension (35) . Recently the CANTOS trial has shown that anti-inflammatory therapy targeting IL-1β may lower the risk of a new CV event in patients with a history of myocardial infarction and blood level of C-reactive protein ≥ 2 mg/L despite the use of aggressive secondary prevention strategies (36) .
RA disease duration has already been associated to an increase in CV risk. However, this association is not linear, with an increased risk already present in the first years of the disease, which remains unchanged thereafter (37) (38) (39) . The use of NSAIDs was not a predictor of MACE in our population. Similarly, a recent Taiwanese nation-wide study did not find an increase in coronary disease in patients taking etoricoxib or celecoxib after adjustment for gender, age, comorbidities, hypertension, hyperlipidemia, and DMARDs (40) . Finding similar results in this study is reassuring, but a confounding by indication cannot be excluded, for example if patients less at risk for MACE are taking more NSAIDs.
Our study has several limitations. We may have a selection bias in our registry, which can have led to either an increased or a decreased estimate in the incidence and prevalence of MACE. Indeed, patients included in the SCQM are more likely to be treated with bDMARDs and thus, comprise a group of more severe patients. However, these patients may also have benefited from better treatments and follow-up, and may also be more aware of their health and prone to follow health advices due to more regular disease assessments (41, 42) . We can also not exclude a survival bias, with patients with less severe rheumatologic or CV conditions included in our register.
The sample of patients for PsA is small and thus the absence of statistically significant difference with RA in the incidence and prevalence of MACE may be due to limited statistical power.
We obtained information on MACE using self-reporting by patients. Questionnaires are often used in epidemiological studies, in the absence of available registries. Validation studies estimates that the sensitivity of self reported myocardial infarction and stroke is moderate to high for both conditions (43, 44) , To minimize this potential reporting bias, we ascertained the results with a physician report.
To investigate the effect of rheumatic diseases on MACE, we chose to exclude patients with a history of non-lethal MACE before the onset of RA, PsA and AxSpa. RA patients are older, and thus at higher risk for MACE. Maybe for this reason, slightly more patients have been excluded for previous MACE in the RA population (1.7%) than in AxSpA (0.3%) or PsA (1.3%). By excluding patients with a previous history MACE, we may have differentially selected patients at lower risk, thus decreasing the difference between RA and the two other rheumatic diseases. Of note, according to one study, the risk of ischemic heart disease does not seem to be increased in RA before the onset of the rheumatic disease, suggesting that MACE occurring before the onset of RA is independent of the rheumatic disease (38) . However, literature is conflicting on this point with another study finding a higher risk of coronary heart disease preceding the ACR criteria based diagnosis of RA (45) .
We could not compare the incidence of MACE of our study population with the general Swiss population, as the data are not reported in the same categories (46, 47) .
We assessed the effect of concomitant medications such as NSAIDS, biological DMARDs and corticosteroids only in the prospective RA cohort, because treatments prescribed before the inclusion in the register were not accurately reported. We also did not adjust for body mass index (BMI), HAQ, or disease activity in patients who were not included in the prospective cohort for the same reason.
Patients were assessed during 10 years on average. In RA, the risk of MACE increased rapidly in the first 4 years of the disease, but we cannot exclude that a longer latency is necessary to see a difference between the diseases (48) .
Finally, a substantial proportion of MACE occurred before the patient's inclusion in the register, which did not allow their inclusion in the analysis of predictors of the incidence of MACE in the RA cohort. Limited statistical power could explain why we did not see an effect of disease activity and NSAID use on MACE, unlike other studies (18, 49, 50) . Accordingly, we could also not use all the prespecified variables in the multivariable analysis, to avoid overadjustment.
The strengths of our study are that the sample is relatively large, with a long duration of follow-up. The data were collected prospectively and included a wide range of variables, including parameters of function and disease activity in the prospective RA cohort.
In conclusion, the incidence and prevalence in MACE in RA was not statistically significantly different to those of AxSpA and PsA after adjustment for confounding factors. However, considering the small sample of patients with PsA, it is difficult to reach a definite conclusion due to limited statistical power. Our findings suggest that inflammation drives the increased risk of CV disease rather than a particular disease. In addition, traditional CV risk factors, such as smoking, hypertension and hyperlipidemia were significantly associated with MACE, stressing the importance of the detection and management of traditional CV risk factors in patients with inflammatory arthritis. Accordingly, the recent recommendations of the EULAR insist on the necessity of clinicians to be aware of the higher risk of CV events in RA, and probably in PsA and AxSpA, and suggest that the rheumatologist should ensure that CV risk management is performed. One of the main recommendations is that an adequate control of disease activity is necessary to lower the CV risk. Thus, additional studies are needed to explore MACE in AxSpA and PsA to better understand the effects of DMARDs and management of CV risk factors on the occurrence of MACE.
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